KC 764
Latest Information Update: 14 Nov 2006
Price :
$50 *
At a glance
- Originator Kyorin Pharmaceutical
- Class Anti-ischaemics; Antiplatelets; Small molecules
- Mechanism of Action Cyclooxygenase inhibitors; Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Intracranial thrombosis; Ischaemic heart disorders; Thrombosis; Transient ischaemic attacks
Most Recent Events
- 31 Mar 1995 Phase-III clinical trials for Thrombosis in Japan (Unknown route)
- 07 Nov 1994 Phase-II clinical trials for Transient ischaemic attacks in Japan (PO)